Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Avastin is a novel antiangiogenic agent that has recently been shown to improve response
rates and survival of patients with advanced nonsquamous non-small cell lung cancer when
added to front-line carboplatin/paclitaxel chemotherapy, and is now being routinely
incorporated into the treatment of these patients. Alimta is a recently approved
chemotherapeutic that has shown activity against non-small cell lung cancer when given alone
and in combination with carboplatin, has a favorable toxicity profile andrequires only a
brief (10 minute) infusion time. Therefore we propose to study the combination of Avasin,
Alimta, and Carboplatin administered as front-line therapy to patients with advanced
nonsquamous non-small cell lung cancer.